Could 3D printing be the future of transplants?

Cara Livernois | | Health Exec | Economics

With a limited supply of readily available transplantable organs, researchers are looking for innovative alternatives for organ transplants—and 3D printing could be an answer.

3D printing has grown leaps and bounds in recent years, with the technology now able to create organ replicas within hours. One day, 3D printing could be improved to develop systems capable of replenishing body cells, pump blood and help patients live longer.

"By quickening the procedure of manufacturing and design, 3D printing helps lower the costs of much-needed medical devices, be it prosthetics or even organ cells," said Eric Johnson, CEO of Rev.1 Engineering. "It will truly be amazing to witness a real-life organ entirely via 3D printing. It would certainly be a much-needed breakthrough."

Read the full story below: 

Artificial Heart Transplants May Be The Future Of Medicine

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Related Content

Bipartisan group of 233 House members call for Medicare reform
Wartime powers enacted to address nationwide IV fluid shortage
Cardiologist compensation still rising, especially in invasive and interventional cardiology
Baxter begins importing IV supplies as 86% of providers report shortages
CMS proposes rule to combat gray market health insurance scams
Private equity firm buys controlling stake in Surescripts

Around the web

Cardiovascular Business
Cardiologist compensation still rising, especially in invasive and interventional cardiology

Updated compensation data includes good news for multiple subspecialties. The new report also examines private equity's impact on employment models and how much male cardiologists earn compared to females.

Cardiovascular Business
FDA’s tirzepatide decision creates uncertainty for patients—and leads to a lawsuit

When drugs are on the FDA’s shortage list, outsourcing facilities can produce their own compounded versions. When the FDA removed tirzepatide from that list with no warning, it created a considerable amount of chaos both behind the scenes and in pharmacies all over the country. 

Cardiovascular Business
Cardiology groups cheer new bill that would improve access to Medicare claims data

If passed, this bill would help clinician-led clinical registries explore Medicare data for research purposes. The Society of Thoracic Surgeons and American College of Cardiology both shared public support for the bipartisan legislation. 

Design by Adaptive Theme
Trimed Popup
Trimed Popup